Abstract:Abstract Glioblastomas (GBM) are treated with high doses of ionizing radiation (IR), yet these tumors inevitably recur, and the recurrent tumors are highly therapy resistant. An understanding of mechanisms driving GBM recurrence is critical for improving therapy. During GBM therapy, both the tumor and normal brain tissue surrounding the tumor are treated with up to 60 Gy of IR. IR is a potent inducer of senescence, and senescent stromal cells can promote the growth of neighboring tumor cells by secreting matrix metalloproteinases, chemokines, cytokines, and growth factors that create a senescence-associated secretory phenotype (SASP). We have shown previously that IR-induced senescence of astrocytes in the brain leads to the secretion of SASP factors that promote the growth and invasiveness of tumor cells in mouse models of GBM (Fletcher-Sananikone, et al, Cancer Research, 2021). Following up on this study, we irradiated a panel of GBM cell lines and found that a significant fraction of these senesced rapidly in a p21-dependent manner. Senescent glioma cells upregulated SASP genes in a NF-kB-dependent manner, prominently, the interleukin IL6, which is an activator of the JAK-STAT pathway. Conditioned media from senescent GBM cells activated the JAK-STAT pathway in non-senescent GBM cells as well as promoted tumor cell proliferation and radioresistance. Interestingly, conditioned media from senescent GBM cells could also activate the NF-kB pathway and induce SASP in non-senescent cells. These results indicate that senescent GBM cells can activate pro-tumorigenic pathways in their non-senescent counterparts and SASP can spread from senescent to non-senescent cells. Bioinformatic analyses of the transcriptomic profiles of irradiated GBM cells and publicly available data from the TCGA database revealed that the inhibitor of apoptosis protein cIAP2 is a critical survival factor for senescent glioma cells. We find that targeting cIAP2 using Smac mimetics triggers apoptosis of senescent GBM cells with minimal toxicity towards normal brain cells, like astrocytes. Upregulation of cIAP2 in irradiated tumor cells was also observed in PDX models of GBM. Using these PDX models, we are currently validating novel senolytic-based therapeutic approaches to mitigate tumor recurrence after radiotherapy. In sum, our findings illustrate how senescence of both stromal and tumor cells promote GBM recurrence via different mechanisms and underscore the potential utility of adjuvant senolytic therapy for blunting GBM recurrence after radiotherapy. Citation Format: Ben R. Jordan, Nozomi Tomimatsu, Luis Macedo Di Cristofaro, Suman Kanji, Bipasha Mukherjee, Sandeep Burma. Radiation-induced senescence as a driver of glioblastoma recurrence [abstract]. In: Proceedings of the AACR Special Conference on Brain Cancer; 2023 Oct 19-22; Minneapolis, Minnesota. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_1):Abstract nr A035.

Advanced in the therapy-induced senescence in glioblastoma

Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma

Cnsc-47. Senolytics Eradicate Senescent Microglia In The Brain Parenchyma And Improve Survival In Older Adult Mice With Glioblastoma

CBIO-11. NOVEL THERAPY TO TARGET PR-RECURRENT GLIOMA

Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype

Elimination of Radiation-Induced Senescence in the Brain Tumor Microenvironment Attenuates Glioblastoma Recurrence

Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy.

Mitochondrial damage triggers therapy-induced senescence

The Advances in Targeted Therapy and Immunotherapy for Glioblastoma: Basic Research and Clinical Trials

Cellular Senescence in Diffuse Gliomas: From Physiopathology to Possible Treatments

The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives

Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?

Abstract PR001: DNA damage-induced senescence as a driver of glioblastoma recurrence

Progress and prospect in tumor treating fields treatment of glioblastoma

Abstract A009: DNA damage-induced senescence as a driver of glioblastoma recurrence

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

Abstract A035: Radiation-induced senescence as a driver of glioblastoma recurrence

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics

Glioblastoma Therapy: Past, Present and Future